These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12081208)

  • 21. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas.
    Zigeuner R; Ratschek M; Langner C
    BJU Int; 2005 Feb; 95(3):315-8. PubMed ID: 15679785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B; Presler M; Matuszewski M
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells.
    Ichwan SJ; Yamada S; Sumrejkanchanakij P; Ibrahim-Auerkari E; Eto K; Ikeda MA
    Oncogene; 2006 Feb; 25(8):1216-24. PubMed ID: 16247456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
    Pavlova S; Mayer J; Koukalova H; Smardova J
    Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract.
    Hayashi H; Furihata M; Kuwahara M; Kagawa S; Shuin T; Ohtsuki Y
    Pathobiology; 2004; 71(2):103-6. PubMed ID: 14707445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1.
    Wesierska-Gadek J; Wojciechowski J; Schmid G
    J Cell Biochem; 2003 Aug; 89(6):1260-84. PubMed ID: 12898523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed expression of apoptotic and cell-cycle control genes in carcinogen-exposed bladders of mice lacking p53.S389 phosphorylation.
    Bruins W; Jonker MJ; Bruning O; Pennings JL; Schaap MM; Hoogervorst EM; van Steeg H; Breit TM; de Vries A
    Carcinogenesis; 2007 Aug; 28(8):1814-23. PubMed ID: 17317680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative genomic hybridization study of arsenic-exposed and non-arsenic-exposed urinary transitional cell carcinoma.
    Hsu LI; Chiu AW; Pu YS; Wang YH; Huan SK; Hsiao CH; Hsieh FI; Chen CJ
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):229-38. PubMed ID: 18201742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro analysis of the dominant negative effect of p53 mutants.
    Chène P
    J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
    Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia.
    Hayashi H; Kuwahara M; Fujisaki N; Furihata M; Ohtsuki Y; Kagawa S
    Oncol Rep; 2001; 8(6):1275-9. PubMed ID: 11605048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
    Kalantari MR; Ahmadnia H
    Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative assessment of the functional p53 status in glioma cells.
    Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
    Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
    Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
    Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
    Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
    Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.